-- 經過三天的假期後,日本股市週四開盤走高,主要受美伊即將達成框架協議以結束這場令全球市場動盪不安、經濟前景黯淡的衝突的猜測提振。 日經225指數上漲728.2點,漲幅1.2%,開盤報60,241.31點。 彭博新聞社週四報道稱,華盛頓方面提出了一份僅有一頁的諒解備忘錄,旨在分階段重新開放具有重要戰略意義的霍爾木茲海峽,並解除美國對伊朗港口的封鎖。 報告也指出,關於伊朗核計畫的詳細談判將在稍後進行,目前尚未達成正式協議。 此前,川普總統決定暫停一項旨在確保商船安全通過霍爾木茲海峽的短暫美國海軍行動。霍爾木茲海峽是全球石油和天然氣運輸的重要通道。 市場目前正等待德黑蘭的官方回應,能源和股票板塊正密切關注局勢緩和的任何跡象。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.